Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surfaxin in ARDS
NCT00215553Phase 2Terminated
- Sponsor
- Windtree Therapeutics, Inc.
- Start
- May 2001
- Primary completion
- Feb 2006
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lucinactant in acute respiratory distress syndrome (ARDS) (7 arms), sponsored by Windtree Therapeutics, Inc. Primary endpoint: Incidence of Patients Being Alive and Not Receiving Mechanical Ventilation for >=48 Hours at the End of Day 28. Started May 2001; status: terminated.
02
Drugs
lucinactant
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT00215553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00215553.